Phase I/II study of intravenous and intraperitoneal paclitaxel for peritoneal metastasis after resection of pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy

Phase I/II study of intravenous and intraperitoneal paclitaxel for peritoneal metastasis after resection of pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy - Intravenous and intraperitoneal paclitaxel for peritoneal metastasis after resection of pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016670

Enrollment

Registered

2015-04-01

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal metastasis after resection of pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy

Interventions

intravenous and intraperitoneal paclitaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Peritoneal recurrence after resection of pancreatic cancer, refractory to gemcitabine and fluoropyrimidine chemotherapy, performance status 0 or 1, adequate bone marrow function, adequate liver function, adequate renal function, obtained informed consent

Exclusion criteria

Exclusion criteria: Metastasis to other distant organsuch as the liver, lungs or bone; other active concomitant malignancies; other severe medical conditions; contraindication of Paclitaxel, Pregnant woman, no informed consent

Design outcomes

Primary

Measure	Time frame
Phase-I: Dose limiting toxicity Phase-II: 2-year survival	—

Countries

Japan

Contacts

Public ContactTsutomu Fujii

Nagoya University Graduate School of Medicine Department of Gastroenterological Surgery (Surgery II)

fjt@med.nagoya-u.ac.jp052-744-2245

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026